 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...477478479480481482483484485486487...522523» |
- || nelarabine / Generic mfg.
Trial primary completion date: Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Feb 17, 2017
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2017 --> Jul 2019
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Roche, Tecentriq (atezolizumab) / Roche
Phase classification, Combination therapy: A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Feb 17, 2017
P1, N=92, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jul 2017 --> Jul 2019 Phase classification: P1b --> P1
- | New P1 trial, PD(L)-1 Biomarker, Surgery: Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 16, 2017
P1, N=12, Recruiting, Sponsor: Presage Biosciences
- | cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Trial primary completion date: Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) (clinicaltrials.gov) - Feb 16, 2017
P3, N=60, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Phase classification: P1b --> P1 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jun 1997
- | doxorubicin hydrochloride / Generic mfg., dexrazoxane / Generic mfg.
Trial primary completion date, Head-to-Head, Metastases: Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 16, 2017
P2, N=73, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Jun 1997 Trial primary completion date: Oct 2022 --> Oct 2023
- | Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
New P2 trial, Combination therapy: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome (clinicaltrials.gov) - Feb 16, 2017
P2, N=20, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, Metastases: LCI-SAR-STS-PEM-001: Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma (clinicaltrials.gov) - Feb 16, 2017
P2, N=30, Not yet recruiting, Sponsor: Edward Kim
- | donepezil / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: PET Evidence of the Effect of Donepezil on Cognitive Performance in an Animal Model of Chemobrain. (Pubmed Central) - Feb 15, 2017
Our results demonstrated the neural mechanisms for cognitive impairment after chemotherapy and show that cognition was improved after donepezil intervention using both behavioral and imaging methods. Our results suggested that donepezil can be employed clinically for the treatment of cognitive deficits after chemotherapy.
- | doxorubicin hydrochloride / Generic mfg.
Journal: The role of the ATM/Chk/P53 pathway in mediating DNA damage in hand-foot syndrome induced by PLD. (Pubmed Central) - Feb 15, 2017
Pegylated liposomal doxorubicin (PLD) has been approved to treat patients with various types of cancers because it rarely caused side effects, such as cardiotoxicity, in comparison to doxorubicin, but it frequently results in hand-foot syndrome (HFS)...In addition, PLD enhanced zebrafish skin pigmentation from the head to the trunk and induced DNA damage (phospho-H2AX staining) and cell death in the skin of zebrafish. The results of the present study suggested potential applications to provide a better understanding of the apoptosis of PLD-treated skin cells and described a simple methodology for detecting a PLD-induced DNA damage response in zebrafish, which may be helpful in preventing and treating HFS.
- |||| Imfinzi (durvalumab) / AstraZeneca, Rituxan (rituximab) / Roche
Enrollment open, Combination therapy, PD(L)-1 Biomarker, IO biomarker: A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Feb 15, 2017
P2, N=120, Recruiting, Sponsor: Celgene
The results of the present study suggested potential applications to provide a better understanding of the apoptosis of PLD-treated skin cells and described a simple methodology for detecting a PLD-induced DNA damage response in zebrafish, which may be helpful in preventing and treating HFS. Not yet recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche
Trial primary completion date: Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Feb 14, 2017
P2, N=105, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2017 --> Feb 2018
- doxorubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 14, 2017
P=N/A, N=6, Completed, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Feb 2017 --> Feb 2018 Recruiting --> Completed | N=40 --> 6 | Initiation date: May 2010 --> Oct 2008 | Trial primary completion date: Apr 2012 --> Jun 2010
- || Xalkori (crizotinib) / Pfizer
Trial primary completion date, Combination therapy: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Feb 14, 2017
P1, N=65, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed | N=40 --> 6 | Initiation date: May 2010 --> Oct 2008 | Trial primary completion date: Apr 2012 --> Jun 2010 Trial primary completion date: Apr 2017 --> Oct 2018
- doxorubicin hydrochloride / Generic mfg.
Enrollment closed, Trial primary completion date: Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer (clinicaltrials.gov) - Feb 14, 2017
P2, N=27, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Apr 2017 --> Oct 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2018
- veliparib (ABT-888) / AbbVie
Trial primary completion date, Combination therapy, PARP Biomarker, Metastases: Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Feb 12, 2017
P1, N=90, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2018 Trial primary completion date: Mar 2017 --> Jun 2017
- |||| mercaptopurine / Generic mfg., thioguanine / Generic mfg.
Trial primary completion date: Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 12, 2017
P3, N=1970, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Mar 2017 --> Jun 2017 Trial primary completion date: Feb 2000 --> Mar 2007
- ||||| topotecan / Generic mfg., cyclophosphamide / Generic mfg., vincristine / Generic mfg.
Enrollment closed, Metastases: AEWS1031: Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma (clinicaltrials.gov) - Feb 11, 2017
P3, N=693, Active, not recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Feb 2000 --> Mar 2007 Suspended --> Active, not recruiting
- ||| Azedra (iobenguane I 131) / Lantheus
Trial completion: Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin (clinicaltrials.gov) - Feb 11, 2017
P=N/A, N=99, Completed, Sponsor: Children's Oncology Group
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- ||| Polivy (polatuzumab vedotin-piiq) / Roche, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed, Enrollment change, Combination therapy: A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 11, 2017
P1/2, N=85, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=110 --> 85
- | doxorubicin hydrochloride / Generic mfg.
Journal: Doxorubicin nanobubble for combining ultrasonography and targeted chemotherapy of rabbit with VX2 liver tumor. (Pubmed Central) - Feb 11, 2017
Ultrasound combined with DOX-NB had significant antitumor effect. Compared with other groups, the tumor growth rate and the proliferation index were the lowest while the survival rate and apoptosis index were the highest.
- | mercaptopurine / Generic mfg., thioguanine / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 9, 2017
P3, N=1970, Completed, Sponsor: Children's Oncology Group
Compared with other groups, the tumor growth rate and the proliferation index were the lowest while the survival rate and apoptosis index were the highest. No longer recruiting --> Completed
- | Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Feb 9, 2017
P2, N=50, Not yet recruiting, Sponsor: Amgen
- ||||| Enrollment closed, Trial primary completion date: Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance (clinicaltrials.gov) - Feb 8, 2017
P3, N=406, Active, not recruiting, Sponsor: Wuerzburg University Hospital
No longer recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Sep 2016
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion, Enrollment change, Trial primary completion date: Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Feb 7, 2017
P1/2, N=14, Completed, Sponsor: Weill Medical College of Cornell University
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Sep 2016 Recruiting --> Completed | N=46 --> 14 | Trial primary completion date: Jan 2013 --> Sep 2013
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New trial: The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma (clinicaltrials.gov) - Feb 7, 2017
P=N/A, N=50, Not yet recruiting, Sponsor: Shanghai Public Health Clinical Center
- | cisplatin / Generic mfg., paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (clinicaltrials.gov) - Feb 6, 2017
P3, N=240, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed | N=46 --> 14 | Trial primary completion date: Jan 2013 --> Sep 2013 Active, not recruiting --> Completed
- || Azedra (iobenguane I 131) / Lantheus
Trial primary completion date: Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=99, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Sep 2016
- || isotretinoin / Generic mfg.
New P3 trial: NB2004-HR: Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients (clinicaltrials.gov) - Feb 2, 2017
P3, N=360, Completed, Sponsor: University of Cologne
- | Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
New P1 trial, Metastases: Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas (clinicaltrials.gov) - Feb 2, 2017
P1b, N=25, Not yet recruiting, Sponsor: University Health Network, Toronto
- doxorubicin encapsulated nanocells (EGFREDVDox) / EnGeneIC
Enrollment open, Trial initiation date, Trial primary completion date: CerebralEDV: A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Feb 2, 2017
P1, N=20, Recruiting, Sponsor: Engeneic Pty Limited
Trial primary completion date: May 2016 --> Sep 2016 Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2017 | Trial primary completion date: Jul 2018 --> Feb 2019
- mitomycin / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: HIPEC/IPHC: Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (clinicaltrials.gov) - Feb 1, 2017
P2, N=200, Recruiting, Sponsor: Bay Area Gynecology Oncology
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Feb 2017 | Trial primary completion date: Jul 2018 --> Feb 2019 Trial primary completion date: Sep 2016 --> Jan 2018
- Herceptin (trastuzumab) / Roche
Trial primary completion date, Tumor cell: Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells (clinicaltrials.gov) - Jan 30, 2017
P2, N=7, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Sep 2016 --> Jan 2018 Trial primary completion date: Sep 2017 --> Oct 2019
- | Opdivo (nivolumab) / BMS
New P1 trial: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) (clinicaltrials.gov) - Jan 30, 2017
P1, N=26, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | New P1 trial, Combination therapy, Metastases, Immune cell: A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 30, 2017
P1, N=36, Not yet recruiting, Sponsor: SYZ Cell Therapy Co..
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases: Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (clinicaltrials.gov) - Jan 30, 2017
P2, N=50, Recruiting, Sponsor: Virginia Commonwealth University
Trial primary completion date: Sep 2017 --> Oct 2019 Not yet recruiting --> Recruiting
- New trial, Surgery: Thrombin Generation and Platelet Activation in CRS/HIPEC (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=27, Completed, Sponsor: Ziekenhuis Oost-Limburg
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) (clinicaltrials.gov) - Jan 30, 2017
P3, N=855, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Venclexta (venetoclax) / Roche, AbbVie
New P1 trial: V+DA-EPOCH-R: Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (clinicaltrials.gov) - Jan 30, 2017
P1, N=18, Not yet recruiting, Sponsor: Weill Medical College of Cornell University
- Trial initiation date: Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation (clinicaltrials.gov) - Jan 26, 2017
P2, N=300, Not yet recruiting, Sponsor: Zhejiang University
Not yet recruiting --> Recruiting Initiation date: Nov 2015 --> Mar 2017
- Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker: Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma (clinicaltrials.gov) - Jan 26, 2017
P2, N=75, Recruiting, Sponsor: Academic and Community Cancer Research United
Initiation date: Nov 2015 --> Mar 2017 Trial primary completion date: Feb 2018 --> Nov 2019
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment open: Subito: Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer (clinicaltrials.gov) - Jan 26, 2017
P3, N=174, Recruiting, Sponsor: The Netherlands Cancer Institute
Trial primary completion date: Feb 2018 --> Nov 2019 Active, not recruiting --> Recruiting
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche, Imbruvica (ibrutinib) / AbbVie, J&J
New P2/3 trial: Ibrutinib for untreated mantle cell lymphoma (EUDRACT) - Jan 24, 2017
P2/3, N=400, Ongoing, Sponsor: Plymouth Hospitals NHS Trust
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial primary completion date: IELSG30: Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis (clinicaltrials.gov) - Jan 24, 2017
P2, N=35, Recruiting, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- thioguanine / Generic mfg.
Trial primary completion date, IO biomarker: CALGB 10403: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 24, 2017
P2, N=300, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Jan 2017 --> Jun 2017
- ||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment closed, Enrollment change, Combination therapy: Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Jan 24, 2017
P2, N=87, Active, not recruiting, Sponsor: Seattle Genetics, Inc.
Trial primary completion date: Jan 2017 --> Jun 2017 Recruiting --> Active, not recruiting | N=125 --> 87
- Enrollment closed: DA-EPOCH-R: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=12, Active, not recruiting, Sponsor: Baylor College of Medicine
Recruiting --> Active, not recruiting | N=125 --> 87 Recruiting --> Active, not recruiting
- Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Jan 24, 2017
P1, N=18, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2017 --> Jan 2017
- doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer (clinicaltrials.gov) - Jan 24, 2017
P2, N=30, Active, not recruiting, Sponsor: Advanced Accelerator Applications
Trial primary completion date: Jun 2017 --> Jan 2017 Trial primary completion date: Dec 2016 --> Sep 2017
- | Campath (alemtuzumab) / Sanofi
Trial completion, IO biomarker: CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas (clinicaltrials.gov) - Jan 23, 2017
P1, N=24, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
Trial primary completion date: Dec 2016 --> Sep 2017 Active, not recruiting --> Completed
- | thioguanine / Generic mfg.
Enrollment closed: International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 23, 2017
P3, N=4750, Active, not recruiting, Sponsor: University of Schleswig-Holstein
Active, not recruiting --> Completed Recruiting --> Active, not recruiting